Selenium enhances the efficacy of Radachlorin mediated-photodynamic therapy in TC-1 tumor development

Kim,Yong-Wan; Bae,Su  Mi; Liu,Hai-Bo; Kim,In-Wook; Chun,Heung-Jae; Ahn,Woong  Shick

doi:10.3892/or.2012.1820

Selenium enhances the efficacy of Radachlorin mediated-photodynamic therapy in TC-1 tumor development

Authors:
- Yong-Wan Kim
- Su Mi Bae
- Hai-Bo Liu
- In-Wook Kim
- Heung-Jae Chun
- Woong Shick Ahn
View Affiliations

Affiliations: Catholic Research Institutes of Medical Science, The Catholic University of Korea, Seoul, Republic of Korea, Institute of Cell and Tissue Engineering, The Catholic University of Korea, Seoul, Republic of Korea, Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Published online on: May 17, 2012 https://doi.org/10.3892/or.2012.1820
Pages: 576-584

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Selenium, an essential trace element possessing anti-carcinogenic properties, can induce apoptosis in cancer cells. Our goal was to investigate the enhanced antitumor effects of photodynamic therapy (PDT) plus selenium in TC-1 tumor cells and implanted mice. Cell viability was evaluated at various time intervals after PDT treatment and/or selenium by methyl thiazolyl tetrazolium (MTT) assay. When only PDT treatment was administered to TC-1 tumor cells, TC-1 cell growth recovered over time. On the other hand, co-treatment of PDT and selenium extended the inhibition time of tumor cell growth. Co-treatment of PDT and selenium showed serious morphological changes in TC-1 cells and induced a more apoptotic population by FACS analysis. By signal transduction pathway SuperArray analysis, genes closely involved in the NFκB, p53 and phopholipase C pathways, such as VCAM1, MDM2 and FOS, were significantly downregulated at least 10-fold in TC-1 cells following PDT and selenium cotreatment. In an in vivo study, tumor-bearing mice were intravenously injected with Radachlorin 3 h before irradiation with 300 J/cm2 of light. Selenium was administered daily for 20 days. Combination therapy against the mouse tumors generated by TC-1 cells was more effective than PDT or selenium alone. These data suggest that selenium plus PDT can induce a significant tumor suppression response compared with PDT alone. Additionally, it can be an effective anticancer therapy strategy.

View Figures

View References

1	Dolmans DE, Fukumura D and Jain RK: Photodynamic therapy for cancer. Nat Rev Cancer. 3:380–387. 2003. View Article : Google Scholar
2	Moghissi K, Dixon K, Thorpe JA, Stringer M and Oxtoby C: Photodynamic therapy (PDT) in early central lung cancer: a treatment option for patients ineligible for surgical resection. Thorax. 62:391–395. 2007. View Article : Google Scholar : PubMed/NCBI
3	Usuda J, Kato H, Okunaka T, et al: Photodynamic therapy (PDT) for lung cancers. J Thorac Oncol. 1:489–493. 2006. View Article : Google Scholar : PubMed/NCBI
4	Klein A, Babilas P, Karrer S, Landthaler M and Szeimies RM: Photodynamic therapy in dermatology - an update 2008. J Dtsch Dermatol Ges. 6:839–846. 2008. View Article : Google Scholar : PubMed/NCBI
5	Biel MA: Photodynamic therapy treatment of early oral and laryngeal cancers. Photochem Photobiol. 83:1063–1068. 2007. View Article : Google Scholar : PubMed/NCBI
6	Dougherty TJ, Gomer CJ, Henderson BW, et al: Photodynamic therapy. J Natl Cancer Inst. 90:889–905. 1998. View Article : Google Scholar
7	Gollnick SO, Evans SS, Baumann H, et al: Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer. 88:1772–1779. 2003. View Article : Google Scholar : PubMed/NCBI
8	Harrison L and Blackwell K: Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist. 9(Suppl 5): 31–40. 2004. View Article : Google Scholar : PubMed/NCBI
9	Vaupel P and Harrison L: Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist. 9(Suppl 5): 4–9. 2004. View Article : Google Scholar : PubMed/NCBI
10	Stadtman TC: Selenium biochemistry. Mammalian selenoenzymes. Ann NY Acad Sci. 899:399–402. 2000. View Article : Google Scholar : PubMed/NCBI
11	Navarro-Alarcon M and Cabrera-Vique C: Selenium in food and the human body: a review. Sci Total Environ. 400:115–141. 2008. View Article : Google Scholar : PubMed/NCBI
12	Jackson MI and Combs GF Jr: Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care. 11:718–726. 2008. View Article : Google Scholar : PubMed/NCBI
13	Letavayova L, Vlckova V and Brozmanova J: Selenium: from cancer prevention to DNA damage. Toxicology. 227:1–14. 2006. View Article : Google Scholar : PubMed/NCBI
14	Pletcher SD, Macdonald SJ, Marguerie R, et al: Genome-wide transcript profiles in aging and calorically restricted Drosophila melanogaster. Curr Biol. 12:712–723. 2002. View Article : Google Scholar : PubMed/NCBI
15	Wang JL, Lin YW, Chen HM, et al: Calcium prevents tumorigenesis in a mouse model of colorectal cancer. PLoS One. 6:e225662011. View Article : Google Scholar : PubMed/NCBI
16	Wilson BC and Patterson MS: The physics, biophysics and technology of photodynamic therapy. Phys Med Biol. 53:R61–R109. 2008. View Article : Google Scholar : PubMed/NCBI
17	Zawacka-Pankau J, Krachulec J, Grulkowski I, Bielawski KP and Selivanova G: The p53-mediated cytotoxicity of photodynamic therapy of cancer: recent advances. Toxicol Appl Pharmacol. 232:487–497. 2008. View Article : Google Scholar : PubMed/NCBI
18	Buytaert E, Dewaele M and Agostinis P: Molecular effectors of multiple cell death pathways initiated by photodynamic therapy. Biochim Biophys Acta. 1776:86–107. 2007.PubMed/NCBI
19	Milde-Langosch K: The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer. 41:2449–2461. 2005. View Article : Google Scholar : PubMed/NCBI
20	Peng QP, Zhou JM, Zhou Q, Pan F, Zhong DP and Liang HJ: Downregulation of the hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil. Chemotherapy. 54:357–363. 2008. View Article : Google Scholar : PubMed/NCBI
21	Zijlmans HJ, Fleuren GJ, Baelde HJ, Eilers PH, Kenter GG and Gorter A: The absence of CCL2 expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2. J Pathol. 208:507–517. 2006. View Article : Google Scholar : PubMed/NCBI
22	Hengstermann A, Linares LK, Ciechanover A, Whitaker NJ and Scheffner M: Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells. Proc Natl Acad Sci USA. 98:1218–1223. 2001. View Article : Google Scholar : PubMed/NCBI
23	Ferrario A, Von Tiehl K, Wong S, Luna M and Gomer CJ: Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res. 62:3956–3961. 2002.PubMed/NCBI
24	Bequet-Romero M and Lopez-Ocejo O: Angiogenesis modulators expression in culture cell lines positives for HPV-16 oncoproteins. Biochem Biophys Res Commun. 277:55–61. 2000. View Article : Google Scholar : PubMed/NCBI
25	Karamysheva AF: Mechanisms of angiogenesis. Biochemistry (Mosc). 73:751–762. 2008. View Article : Google Scholar
26	Deng CX: BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res. 34:1416–1426. 2006. View Article : Google Scholar : PubMed/NCBI
27	Yen CY, Chen CH, Chang CH, et al: Matrix metalloproteinases (MMP) 1 and MMP10 but not MMP12 are potential oral cancer markers. Biomarkers. 14:244–249. 2009. View Article : Google Scholar : PubMed/NCBI
28	Wu TC: The role of vascular cell adhesion molecule-1 in tumor immune evasion. Cancer Res. 67:6003–6006. 2007. View Article : Google Scholar : PubMed/NCBI
29	Zender L, Spector MS, Xue W, et al: Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 125:1253–1267. 2006. View Article : Google Scholar : PubMed/NCBI
30	Ma O, Cai WW, Zender L, et al: MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res. 69:2559–2567. 2009. View Article : Google Scholar : PubMed/NCBI
31	Khor TO, Gul YA, Ithnin H and Seow HF: A comparative study of the expression of Wnt-1, WISP-1, survivin and cyclin-D1 in colorectal carcinoma. Int J Colorectal Dis. 21:291–300. 2006. View Article : Google Scholar : PubMed/NCBI
32	Xie D, Nakachi K, Wang H, Elashoff R and Koeffler HP: Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res. 61:8917–8923. 2001.PubMed/NCBI